Dr. Bryan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1411 Laney Walker Blvd
Augusta, GA 30912Phone+1 706-721-6744Fax+1 706-721-5566
Summary
- Dr. Locke Bryan is a hematologist in Augusta, GA and is affiliated with Augusta University Medical Center. He received his medical degree from University of Mississippi School of Medicine and has been in practice 9 years. He specializes in hematologic oncology and is experienced in hematology / oncology and stem cell transplant.
Education & Training
McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2012 - 2015
University of Vermont Medical CenterResidency, Internal Medicine, 2008 - 2011
University of Mississippi School of MedicineClass of 2008
Certifications & Licensure
GA State Medical License 2015 - 2025
IL State Medical License 2012 - 2017
VT State Medical License 2008 - 2012- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission Start of enrollment: 2015 Sep 01
- Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2017 Apr 21
- Study of IMPT-314 in R/R Aggressive B-cell NHL Start of enrollment: 2023 May 09
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 23 citationsPembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investiga...Locke J Bryan, Carla Casulo, Pamela B Allen, Scott E Smith, Hatice Savas
JAMA Oncology. 2023-05-01 - 5 citationsIndomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapy.Nada S Aboelella, Caitlin Brandle, Ogacheko Okoko, Md Yeashin Gazi, Zhi-Chun Ding
Journal for Immunotherapy of Cancer. 2022-07-01 - 8 citationsPhase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma.Ahmad S Halwani, Carlos Panizo, Iris Isufi, Alex F Herrera, Craig Y Okada
Leukemia & Lymphoma. 2022-04-01
Press Mentions
Antibiotic Use May Affect Efficacy of Cancer ImmunotherapiesMarch 3rd, 2018
Antibiotics Influence Cancer Treatment EfficacyMarch 3rd, 2018
Scientists Work to Strengthen the Synergy of Chemotherapy and Immunotherapy Against CancerApril 17th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
